CME: Fabry disease: Updates from recent research findings
Cost: FreeView Offer chevron_right
Fabry disease is characterized by a deficiency of the glycoside hydrolase enzyme alpha galactosidase A, resulting in the accumulation of the glycolipid globotriaosylceramide throughout the body, particularly prominently in the blood vessels.
After completing this course, physicians will better be able to:
- Describe the pathogenesis, clinical presentations, complications, and epidemiology of Fabry disease including updated material presented at the 15th Annual WORLDSymposium
- Describe principles and problems regarding screening for and diagnosing Fabry disease that can applied to patient cases
- Describe emerging therapies for Fabry disease based on research presented at the 15th Annual WORLDSymposium
- Design and implement appropriate therapeutic plans for treatment of Fabry disease based on research presented at the 15th Annual WORLDSymposium
Target Audience: cardiologists, nephrologists, pediatricians, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists; and any other healthcare professionals with an interest in or who may clinically encounter patients with Fabry disease.